[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-4-[2-(1-piperidinyl)ethoxy]phenyl malonate | 676636-17-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-4-[2-(1-piperidinyl)ethoxy]phenyl malonate
• 英文别名: [6-Hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;propanedioic acid
• CAS: 676636-17-2
• 化学式: C₃H₄O₄*C₂₈H₂₇NO₄S
• 分子量: 577.655
• InChiKey: BKGBQLVGRTVQCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.62
• 重原子数：
  41
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  173
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  丙二酸 、 盐酸雷洛昔芬 在 氢氧化钾 作用下， 以 异丙醇 、 水 为溶剂， 反应 20.25h， 以97%的产率得到[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-4-[2-(1-piperidinyl)ethoxy]phenyl malonate
  参考文献：
  名称：

  [EN] NOVEL RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF, IMPROVED METHOD FOR PURIFICATION OF SAID RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE
  [FR] NOUVEAUX SELS D'ADDITION ACIDES DE RALOXIFENE ET/OU SOLVATES DE CEUX-CI, PROCEDE AMELIORE PERMETTANT LA PURIFICATION DE CES SELS D'ADDITION ACIDES ET/OU DE CES SOLVATES, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

  摘要：

  公开号：

  WO2004029046A3

文献信息

• Novel raloxifene succinic acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these
  申请人：A/S GEA Farmaceutisk Fabrik

  公开号：EP1826205A1

  公开（公告）日：2007-08-29

  Raloxifene succinic acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed succinic acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene succinic acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation.

  与基于雷洛昔芬或盐酸雷洛昔芬的类似制剂相比，雷洛昔芬琥珀酸加成盐或其溶解物在含有盐酸的介质中具有更好的溶解特性。所公开的琥珀酸加成盐或其溶解物在含有盐酸的介质（如胃液）中显示出更好的生物利用度。此外，还公开了结晶形式的雷洛昔芬盐及其溶液。 雷洛昔芬琥珀酸加成盐和/或其溶解物可用于制备口服药物组合物，能够在患者胃中快速、可靠地释放活性成分，特别是用于治疗癌症或骨质疏松症，或抑制软骨降解。
• Novel raloxifene malonic acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these
  申请人：A/S GEA Farmaceutisk Fabrik

  公开号：EP1832582A1

  公开（公告）日：2007-09-12

  Raloxifene malonic acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed malonic acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene malonic acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation.

  与基于雷洛昔芬或盐酸雷洛昔芬的类似制剂相比，雷洛昔芬丙二酸加成盐或其溶解物在含有盐酸的介质中具有更好的溶解特性。所公开的丙二酸加成盐或其溶解物在含有盐酸的介质（如胃液）中显示出更好的生物利用度。此外，还公开了结晶形式的雷洛昔芬盐及其溶解物。 雷洛昔芬丙二酸加成盐和/或其溶解物可用于制备口服药物组合物，能够在患者胃中快速、可靠地释放活性成分，特别是用于治疗癌症或骨质疏松症，或抑制软骨降解。
• Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these
  申请人：A/S GEA Farmaceutisk Fabrik

  公开号：EP1832583A1

  公开（公告）日：2007-09-12

  Raloxifene sulphuric acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed sulphuric acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene sulphuric acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation.

  与基于雷洛昔芬或盐酸雷洛昔芬的类似制剂相比，雷洛昔芬硫酸添加盐或其溶解物在含有盐酸的介质中具有更好的溶解特性。所公开的硫酸加成盐或其溶解物在含有盐酸的介质（如胃液）中显示出更好的生物利用度。此外，还公开了结晶形式的雷洛昔芬盐及其溶解物。 雷洛昔芬硫酸加成盐和/或其溶解物可用于制备口服药物组合物，能够在患者胃中快速、可靠地释放活性成分，特别是用于治疗癌症或骨质疏松症，或用于抑制软骨降解。
• Novel raloxifene acid additon salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
  申请人：Karup Leo Gunnar

  公开号：US20060154966A1

  公开（公告）日：2006-07-13

  Raloxifene acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. The acid addition salts or solvates thereof are addition salts or solvates of raloxifene and a pharmaceutical acceptable acid selected among succinic acid, lactic acid, malonic acid or sulphuric acid. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation. A new method for preparation of raloxifene lactate is also disclosed.

  与基于雷洛昔芬或盐酸雷洛昔芬的类似制剂相比，雷洛昔芬酸加成盐或其溶解物在含有盐酸的介质中具有更好的溶解特性。所公开的酸加成盐或其溶解物在含有盐酸的介质（如胃液）中显示出更好的生物利用度。其酸加成盐或溶解物是雷洛昔芬和选自琥珀酸、乳酸、丙二酸或硫酸的药物可接受酸的加成盐或溶解物。此外，还公开了雷洛昔芬盐及其溶液的结晶形式。雷洛昔芬酸加成盐和/或其溶解物可用于制备口服药物组合物，能够在患者胃中快速、可靠地释放活性成分，特别是用于治疗癌症或骨质疏松症，或用于抑制软骨降解。此外，还公开了一种制备乳酸雷洛昔芬的新方法。
• NOVEL RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF, IMPROVED METHOD FOR PURIFICATION OF SAID RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE
  申请人：A/S GEA Farmaceutisk Fabrik

  公开号：EP1546138A2

  公开（公告）日：2005-06-29